Skip to content

Charles River Laboratories International

NYSE: CRL · USD

Charles River Laboratories International revenue87

Quarterly and annual revenue from company filings.

Business drivers

Business lines and operating measures.

Total DSA revenue

Reported quarterly Total DSA revenue. Quarterly figures · USD

Total DSA revenue. Reported quarterly Total DSA revenue. Unit: USD. All reporting dates and source links follow.
Period endedUSDReport
Jun 27, 2026From Mar 29, 2026606,507,000Filed Aug 5, 2026
Mar 28, 2026From Dec 28, 2025596,923,000Filed May 7, 2026
Jun 28, 2025From Mar 30, 2025618,029,000Filed Aug 5, 2026
Mar 29, 2025From Dec 29, 2024592,609,000Filed May 7, 2026

Total RMS revenue

Reported quarterly Total RMS revenue. Quarterly figures · USD

Total RMS revenue. Reported quarterly Total RMS revenue. Unit: USD. All reporting dates and source links follow.
Period endedUSDReport
Jun 27, 2026From Mar 29, 2026209,475,000Filed Aug 5, 2026
Mar 28, 2026From Dec 28, 2025208,367,000Filed May 7, 2026
Jun 28, 2025From Mar 30, 2025213,271,000Filed Aug 5, 2026
Mar 29, 2025From Dec 29, 2024213,073,000Filed May 7, 2026

Total Manufacturing revenue

Reported quarterly Total Manufacturing revenue. Quarterly figures · USD

Total Manufacturing revenue. Reported quarterly Total Manufacturing revenue. Unit: USD. All reporting dates and source links follow.
Period endedUSDReport
Jun 27, 2026From Mar 29, 2026188,096,000Filed Aug 5, 2026
Mar 28, 2026From Dec 28, 2025190,540,000Filed May 7, 2026
Jun 28, 2025From Mar 30, 2025200,835,000Filed Aug 5, 2026
Mar 29, 2025From Dec 29, 2024178,486,000Filed May 7, 2026

Independent series; they may overlap and do not form an additive breakdown.

  • Divestitures affect comparability across periods.
  • The supplied proposals contain no nonfinancial operating measures.

Products & projects

Research Model Services

Research Model Services includes: Insourcing Solutions (IS), which provides colony management of our clients’ research operations (including recruitment, training, staffing, and management services) within our clients’ facilities as well as our own vivarium space, utilizing our Charles River Accelerator and Development Lab (CRADL™) offerings, Genetically Engineered Models and Services (GEMS), which performs contract breeding and other services associated with genetically engineered models; and Research Animal Diagnostic Services (RADS), which provides health monitoring and diagnostics services related to research models.

Filed · source for Research Model Services

Endosafe® Trillium®

We also manufacture sterility and microbial limits test kits used in FDA Regulated pharmaceutical applications, reagents, cell banks used in research and biopharmaceutical production, clinical trial vaccines and vaccine support products as well as an animal-free recombinant cascade reagent (rCR), Endosafe® Trillium®, which is an alternative to the natural LAL product.

Filed · source for Endosafe® Trillium®

Revenue history

USD millions · Fiscal periods
Jun 26, 2010 through Jun 27, 2026

Quarterly data

Charles River Laboratories International quarterly financial data in USD millions. FY denotes the company's fiscal year. YTD covers reported quarters only.
Fiscal quarterEndedTotal revenueUSD millions
FY 2026 Q2Jun 27, 20261,004.078, +0.8% versus FY 2026 Q1
FY 2026 Q1Mar 28, 2026995.83, +0.2% versus FY 2025 Q4
FY 2025 Q4Dec 27, 2025994.227, −1.1% versus FY 2025 Q3
FY 2025 Q3Sep 27, 20251,004.852, −2.6% versus FY 2025 Q2
FY 2025 Q2Jun 28, 20251,032.135, +4.9% versus FY 2025 Q1
FY 2025 Q1Mar 29, 2025984.168, −1.8% versus FY 2024 Q4
FY 2024 Q4Dec 28, 20241,002.549, −0.7% versus FY 2024 Q3
FY 2024 Q3Sep 28, 20241,009.763, −1.6% versus FY 2024 Q2
FY 2024 Q2Jun 29, 20241,026.117, +1.4% versus FY 2024 Q1
FY 2024 Q1Mar 30, 20241,011.56, −0.2% versus FY 2023 Q4
FY 2023 Q4Dec 30, 20231,013.476, −1.3% versus FY 2023 Q3
FY 2023 Q3Sep 30, 20231,026.623, −3.1% versus FY 2023 Q2
FY 2023 Q2Jul 1, 20231,059.937, +3.0% versus FY 2023 Q1
FY 2023 Q1Apr 1, 20231,029.373, −6.4% versus FY 2022 Q4
FY 2022 Q4Dec 31, 20221,099.843, +11.2% versus FY 2022 Q3
FY 2022 Q3Sep 24, 2022989.157, +1.6% versus FY 2022 Q2
FY 2022 Q2Jun 25, 2022973.131, +6.5% versus FY 2022 Q1
FY 2022 Q1Mar 26, 2022913.929, +1.0% versus FY 2021 Q4
FY 2021 Q4Dec 25, 2021905.05, +1.0% versus FY 2021 Q3
FY 2021 Q3Sep 25, 2021895.937, −2.0% versus FY 2021 Q2
FY 2021 Q2Jun 26, 2021914.607, +10.9% versus FY 2021 Q1
FY 2021 Q1Mar 27, 2021824.566, +4.2% versus FY 2020 Q4
FY 2020 Q4Dec 26, 2020790.99, +6.4% versus FY 2020 Q3
FY 2020 Q3Sep 26, 2020743.3, +8.9% versus FY 2020 Q2
FY 2020 Q2Jun 27, 2020682.584, −3.5% versus FY 2020 Q1
FY 2020 Q1Mar 28, 2020707.059, +2.3% versus FY 2019 Q4
FY 2019 Q4Dec 28, 2019691.138, +3.5% versus FY 2019 Q3
FY 2019 Q3Sep 28, 2019667.951, +1.6% versus FY 2019 Q2
FY 2019 Q2Jun 29, 2019657.568, +8.8% versus FY 2019 Q1
FY 2019 Q1Mar 30, 2019604.569, +0.5% versus FY 2018 Q4
FY 2018 Q4Dec 29, 2018601.53, +2.8% versus FY 2018 Q3
FY 2018 Q3Sep 29, 2018585.295, 0.0% versus FY 2018 Q2
FY 2018 Q2Jun 30, 2018585.301, +18.5% versus FY 2018 Q1
FY 2018 Q1Mar 31, 2018493.97, +3.2% versus FY 2017 Q4
FY 2017 Q4Dec 30, 2017478.477, +3.1% versus FY 2017 Q3
FY 2017 Q3Sep 30, 2017464.232, −1.0% versus FY 2017 Q2
FY 2017 Q2Jul 1, 2017469.129, +5.2% versus FY 2017 Q1
FY 2017 Q1Apr 1, 2017445.763, −4.5% versus FY 2016 Q4
FY 2016 Q4Dec 31, 2016466.789, +9.6% versus FY 2016 Q3
FY 2016 Q3Sep 24, 2016425.72, −1.9% versus FY 2016 Q2
FY 2016 Q2Jun 25, 2016434.055, +22.3% versus FY 2016 Q1
FY 2016 Q1Mar 26, 2016354.868, +0.3% versus FY 2015 Q4
FY 2015 Q4Dec 26, 2015353.85, +1.3% versus FY 2015 Q3
FY 2015 Q3Sep 26, 2015349.465, +2.9% versus FY 2015 Q2
FY 2015 Q2Jun 27, 2015339.573, +6.0% versus FY 2015 Q1
FY 2015 Q1Mar 28, 2015320.414, −2.8% versus FY 2014 Q4
FY 2014 Q4Dec 27, 2014329.548, +0.6% versus FY 2014 Q3
FY 2014 Q3Sep 27, 2014327.567, −4.0% versus FY 2014 Q2
FY 2014 Q2Jun 28, 2014341.179, +14.0% versus FY 2014 Q1
FY 2014 Q1Mar 29, 2014299.368, +3.5% versus FY 2013 Q4
FY 2013 Q4Dec 28, 2013289.228, −1.0% versus FY 2013 Q3
FY 2013 Q3Sep 28, 2013292.129, −0.3% versus FY 2013 Q2
FY 2013 Q2Jun 29, 2013292.933, +0.6% versus FY 2013 Q1
FY 2013 Q1Mar 30, 2013291.238, +4.0% versus FY 2012 Q4
FY 2012 Q4Dec 29, 2012280.14, +0.5% versus FY 2012 Q3
FY 2012 Q3Sep 29, 2012278.686, −2.1% versus FY 2012 Q2
FY 2012 Q2Jun 30, 2012284.723, −0.4% versus FY 2012 Q1
FY 2012 Q1Mar 31, 2012285.981, −1.7% versus FY 2011 Q4
FY 2011 Q4Dec 31, 2011290.962, +4.8% versus FY 2011 Q3
FY 2011 Q3Sep 24, 2011277.579, −3.7% versus FY 2011 Q2
FY 2011 Q2Jun 25, 2011288.263, +0.8% versus FY 2011 Q1
FY 2011 Q1Mar 26, 2011285.843, +6.7% versus FY 2010 Q4
FY 2010 Q4Dec 25, 2010267.886, −3.0% versus FY 2010 Q3
FY 2010 Q3Sep 25, 2010276.081, −5.5% versus FY 2010 Q2
FY 2010 Q2Jun 26, 2010292.104, Change unavailable versus FY 2010 Q1
Sources and definitions

Figures from official company filings and financial reports, in the reported currency. FY identifies the fiscal year; the end date identifies the calendar period. Last checked Oct 19, 2026.

Annual values come from annual filings. Historical quarters retain their reporting basis; rounding and reclassifications can make their sum differ from the annual figure. YTD sums the available fiscal quarters and compares the same quarters of the previous fiscal year.

Missing values are shown as unavailable. Fourth quarters use reported values where available, otherwise the annual amount less the matching nine-month amount.

Total revenue
Reported consolidated revenue from the issuer filing. Each observation identifies its accounting concept; bank net revenue is net of interest expense when that concept is reported.